<DOC>
	<DOCNO>NCT01427504</DOCNO>
	<brief_summary>The investigator believe boceprevir 's drug concentration reduce administered combination etravirine . The investigator believe etravirine 's drug concentration increase administer combination boceprevir . Additionally , investigator believe boceprevir etravirine safe administer alone combination .</brief_summary>
	<brief_title>Potential Drug-drug Interactions Between Boceprevir Etravirine HIV/Hepatitis C Virus Negative Volunteers</brief_title>
	<detailed_description>To investigate potential drug interaction boceprevir etravirine , participant receive drug alone drug combination 11-14 day . The pharmacokinetics boceprevir etravirine give combination vs. alone compare .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Men woman age 1860 year Absence HIV1 HCV antibodies screen Ability willingness give write informed consent first trialrelated activity Pregnancy Breastfeeding Active alcohol drug abuse , opinion investigator , would interfere adherence study requirement . Participation investigation drug study within 30 day prior study . Currently active chronic gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease malignancy require pharmacologic treatment , and/or opinion investigator , would affect study participation , safety , integrity result . Use concomitant medication , include investigational , prescription , overthecounter product dietary supplement follow exception : aspirin , acetaminophen , daily multivitamin , mineral supplement hormonal oral contraceptive ( contain drospirenone ) . Concomitant medication list must discontinue least 14 day study entry . Currently active dermatitis urticaria diagnosis eczema psoriasis . History significant drug allergy ( i.e. , anaphylaxis and/or angioedema ) Subjects follow laboratory abnormality screen defined 2004 Division AIDS Table grade Severity Adult Pediatric Adverse Events accordance normal range trial clinical laboratory : serum creatinine grade 1 great ( &gt; 1.1 x upper limit laboratory normal range ( ULN ) ; hemoglobin grade 1 great ( ≤ 10.9 g/dL ) ; platelet count grade 1 great ( ≤ 124.999 x 109/L ) ; absolute neutrophil count grade 1 great ( ≤ 1.3 x 109/L ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( ≥ 1.25 x ULN ) ; total bilirubin grade 1 great ( ≥ 1.1 x ULN ) , laboratory abnormality grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
</DOC>